Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-finding study of fosalvudine tidoxil in antiretroviral-naive HIV-1 infected patients
2006-001107-10Phase 2Completed
- Sponsor
- Heidelberg Pharma AG
- Start
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fosalvudine tidoxil in Human immunodeficiency virus infection type 1 (5 arms), sponsored by Heidelberg Pharma AG. Primary endpoints: Safety and tolerability (adverse events) across doses of HDP 99.0003 and Pharmacokinetics of HDP 99.0003 at each dose group. Started Mar 2006; status: completed.
02
Drugs
fosalvudine tidoxil
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2006-001107-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001107-10.